A detailed history of Zeke Capital Advisors, LLC transactions in Kiromic Biopharma, Inc. stock. As of the latest transaction made, Zeke Capital Advisors, LLC holds 107,000 shares of KRBP stock, worth $107,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,000
Previous 107,000 -0.0%
Holding current value
$107,000
Previous $31,000 38.71%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

BUY
$0.6 - $1.82 $30,060 - $91,183
50,101 Added 88.05%
107,000 $91,000
Q3 2021

Nov 15, 2021

BUY
$2.69 - $4.94 $107,600 - $197,600
40,000 Added 236.7%
56,899 $175,000
Q2 2021

Aug 16, 2021

SELL
$4.81 - $10.34 $144,781 - $311,234
-30,100 Reduced 64.04%
16,899 $81,000
Q1 2021

Apr 21, 2021

SELL
$8.2 - $11.81 $11,479 - $16,534
-1,400 Reduced 2.89%
46,999 $442,000
Q4 2020

Feb 10, 2021

BUY
$8.11 - $11.5 $392,515 - $556,588
48,399 New
48,399 $410,000

Others Institutions Holding KRBP

# of Institutions
2
Shares Held
107K
Call Options Held
0
Put Options Held
0

About Kiromic Biopharma, Inc.


  • Ticker KRBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,843,200
  • Market Cap $15.8M
  • Description
  • Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate tar...
More about KRBP
Track This Portfolio

Track Zeke Capital Advisors, LLC Portfolio

Follow Zeke Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zeke Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Zeke Capital Advisors, LLC with notifications on news.